Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Lung Neoplasms 53Leukemia, Myeloid, Acute 52Neoplasm Metastasis 45Carcinoma, Non-Small-Cell Lung 40Prostatic Neoplasms 37Breast Neoplasms 36Multiple Myeloma 31Colorectal Neoplasms 29Pancreatic Neoplasms 26Carcinoma, Renal Cell 25Melanoma 23Ovarian Neoplasms 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 20Lymphoma 20Leukemia, Lymphocytic, Chronic, B-Cell 20Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Urinary Bladder Neoplasms 16Carcinoma, Hepatocellular 16Squamous Cell Carcinoma of Head and Neck 15Glioblastoma 15Fallopian Tube Neoplasms 14Oropharyngeal Neoplasms 13Glioma 13Endometrial Neoplasms 13Sarcoma 12Mouth Neoplasms 12Lymphoma, Non-Hodgkin 12

Interventions

Dexamethasone 7Bortezomib 6Cyclophosphamide 5daratumumab 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3venetoclax 2dexamethasone acetate 2dexamethasone 21-phosphate 2belantamab mafodotin 2auricularum 2X-Rays 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Calcium Dobesilate 2Biopsy 2ixazomib 1Tissue Banks 1Stem Cell Transplantation 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Specimen Handling × 90 days × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05898646 2026-03-30

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Mayo Clinic

Phase 2 Recruiting
96 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡